Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced on 1/28/19 that it is commencing a public offering of 8,000,000 Class A common shares. In addition, Kiniksa... read more
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced on 1/28/19 that it is commencing a public offering of 8,000,000 Class A common shares. In addition, Kiniksa... read more
MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced on 1/26/19 that it was informed that in its lawsuit against Janssen Biotech and Genmab A/S, the United... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,